Latest news with #OBG
Yahoo
13-05-2025
- Business
- Yahoo
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the quarter with US$13.8 million in cash Advancing Phase 2 clinical trial with Avenanthramide product Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer TORONTO, ONTARIO, May 13, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ('COSCIENS' or the 'Company'), a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today reported its financial and operating results for the first quarter ended March 31, 2025 and provided a corporate update. Pharmaceuticals: Avenanthramides Tablets in Clinical Development as an Anti-Inflammatory Product: During the first quarter of 2025, the Company announced successful Phase 1 results from the Phase 1 clinical study of its Avenanthramides tablets. That study involved 72 healthy subjects. There were no significant clinical adverse events observed from ascending doses ranging from 30 mg to 960 mg of the Company's Avenanthramides tablets in that Phase 1 clinical study. As a result of the successful completion of that Phase 1 clinical study, the Company launched a Phase 2a clinical efficacy study of its Avenanthramides tablets on March 15, 2025. That study includes 20 patients divided in two cohorts. The first cohort of 10 patients who received a daily dose of 480 mg is completed. Subsequent to the end of the first quarter, data from those 10 patients was reviewed by independent members of the Data and Safety Monitoring Board (DSMB). The DSMB recommended that the study continue as planned with a second cohort of 10 patients who will receive a daily dose of 960 mg. The Company's goal remains to complete the Phase 2a Clinical Efficacy Study during Q3, 2025. Nutraceuticals: The COSCIENS team is working to commercialize a new portfolio of nutraceuticals leveraging the deep understanding and expertise in the active ingredients category and marking an important chapter in the Company's journey toward promoting wellness while expanding its business model. Those include: Oat Beta Glucan (OBG) Chewable Bar – Cholesterol Reduction: We have successfully developed a unique, standardized formulation for a healthy confection which includes a high concentration of OBG with daily dosage according to approved OBG product monograph in 10 developed countries. Yeast Beta Glucan (YBG) Powder - Immune Booster: Our YBG product has been successfully manufactured as part of our PGX scale-up project in Edmonton, Alberta. Our YBG product is being finalized in capsule form with the goal to commercialize it as an immune booster. Technology: Pressurized Gas eXpanded Technology (PGX Technology): Edmonton Main Facility PGX Scale Up 50 Liters Vessel: The project is completed and the equipment is ready to produce YBG at a small-scale commercial level. Summary of First Quarter 2025 Financial Results All amounts are in U.S. Company had $13.8 million in cash and cash equivalents at March 31, the three-month period ended March 31, 2025, we reported a consolidated net loss of $3.7 million, or $1.16 loss per common share, as compared with a consolidated net loss of $1.4 million, or $0.76 loss per common share for the same period in 2024. The $2.3 million increase in net loss is primarily due to increases in operating expenses of $1.4 million, a $0.5 million decrease in gross margin, and a decrease of $0.4 million in income tax recoveries. Revenues Our total revenue for the three-month period ended March 31, 2025, was $1.5 million as compared to $2.1 million for the same period in 2024, a decrease of $0.6 million. This decrease was primarily due to a $0.7 million decrease in sales of Avenanthramides, Beta Glucan, and Oat Oil from prior period, offset by $0.1 million in Macrilen revenue. Operating Expenses Our total operating expenses for the three-month period ended March 31, 2025, were $4.0 million as compared with $2.7 million for the same period in 2024. This increase of $1.3 million was due to higher selling, general and administrative costs of $1.2 million due primarily to the merger completed in June 2024 between Aeterna (now COSCIENS) and Ceapro, as well as a slight increase in research and development costs of $0.1 million related mainly to timing and residual expenses associated with certain post-trial activities related to the DETECT trial. Since the merger, we have successfully reduced overall spend by leveraging restructuring initiatives and operational synergies. This is reflected in our quarter-over-quarter reduction in cash spend, decreasing from $3.6M in Q4 2024 to $2.6M in Q1 2025. Consolidated Financial Statements and Management's Discussion and Analysis For reference, the Management's Discussion and Analysis of Financial Condition and Results of Operations for the first quarter of 2025, as well as the Company's consolidated financial statements as of March 31, 2025, will be available on the Company's website ( in the Investors section or at the Company's SEDAR+ and EDGAR profiles at and respectively. About COSCIENS Biopharma is a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products. Our technology includes proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals. Our consolidated portfolio also includes macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency ('AGHD'). The company is listed on the NASDAQ Capital Market and the Toronto Stock Exchange, and trades on both exchanges under the ticker symbol "CSCI". For more information, please visit COSCIENS' website at Statements Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward-looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to: our plans for the Phase 2a Clinical Efficacy Study of its Avenanthramides tablets, our goal to commercialize our nutraceutical products (including our OBG chewable bar and YBG powder), the potential of our PGX technology and our goals and expectations regarding our other plans related to the development, manufacture or commercialization of our products. Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic, operational and other risks, uncertainties, contingencies and other factors, including those described below, which could cause actual results, performance or achievements of the combined Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements and, as such, undue reliance must not be placed on them. Forward-looking statements involve known and unknown risks and uncertainties which include, among others: the combined Company's present and future business strategies; operations and performance within expected ranges; anticipated future cash flows; local and global economic conditions and the environment in which the combined Company operates; anticipated capital and operating costs; uncertainty in our revenue generation from our marketed products, product development and related clinical trials and validation studies; results from our products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary endpoint in children (CGHD) may impact the market for macimorelin (Macrilen®; Ghryvelin®) in adults (AGHD) and the existing relationships we have for that product; ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on sales by and revenue from our main distributor of our legacy Ceapro products and its customers, the continued availability of funds and resources to successfully commercialize our products; the ability to secure strategic partners for late stage development, marketing, and distribution of our products; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to protect and enforce our patent portfolio and intellectual property; and our ability to continue to list our common shares on the NASDAQ Capital Market. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those discussed in our Annual Report on Form 20-F and MD&A filed under the Company's profile on SEDAR+ at and on EDGAR at We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release. Issuer: Anna BiehnChief Executive OfficerE: ABiehn@ Investor Contact:Jenene ThomasJTC Team T: (US): +1 (908) 824-0775E: csci@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Arabian Business
06-05-2025
- Business
- Arabian Business
Ajman emerges as key UAE investment hub with free zones and SME growth, says report
The emirate of Ajman continues to establish itself as a competitive investment destination within the UAE's broader economy, an industry report said. Its strategic proximity to Dubai enables seamless connectivity to global markets while maintaining lower operational costs, making it an attractive base for small and medium-sized enterprises (SMEs) and high-growth industries, said the report, titled 'Ajman 2025', by Oxford Business Group (OBG). 'The emirate has demonstrated resilience and growth across key sectors, particularly in manufacturing, real estate, and logistics, supported by initiatives such as the Ajman Free Zone and 100 per cent foreign ownership laws,' OBG said. It said infrastructure developments in transport and logistics, alongside the construction of mixed-use real estate projects, underline the Ajman government's commitment to diversification and economic expansion. The streamlining of trade practices through digital solutions and regulatory enhancements is further strengthening the emirate's business environment, while increased integration of the industrial sector into global supply chains is positioning it as a competitive player in international trade, the report said. Additionally, the emirate is leveraging its strategic location to expand its cultural and tourism offerings, reinforcing its appeal as a business and lifestyle destination. Jana Treeck, OBG's Managing Director for the Middle East, said Ajman's strategic approach to economic diversification is reinforcing its status as a key investment destination. 'Ajman's proactive economic policies, combined with regulatory reforms and infrastructure development, are enhancing the emirate's attractiveness to investors. 'Its efforts to modernise industries and integrate digital solutions reflect a broader commitment to fostering sustainable and inclusive economic growth,' he said. The report, developed in collaboration with the Ajman Executive Council and featuring exclusive insights from key policymakers and business leaders, covers a wide range of sectors, including macroeconomics, infrastructure, finance, manufacturing, and ICT.
Zawya
06-05-2025
- Business
- Zawya
Ajman an attractive base for SMEs, industries: report
The emirate of Ajman continues to establish itself as a competitive investment destination within the UAE's broader economy, says a new report. Its strategic proximity to Dubai enables seamless connectivity to global markets while maintaining lower operational costs, making it an attractive base for small and medium-sized enterprises (SMEs) and high-growth industries, says The Report: Ajman 2025 by Oxford Business Group (OBG). Developed in collaboration with the Ajman Executive Council, the report says Ajman's dynamic economic expansion is bolstered by a diversified industrial base and strategic location. The Report: Ajman 2025 offers a comprehensive analysis of the emirate's investment landscape and long-term growth strategies. The emirate has demonstrated resilience and growth across key sectors, particularly in manufacturing, real estate, and logistics, supported by initiatives such as the Ajman Free Zone and 100% foreign ownership laws. Infrastructure developments in transport and logistics, alongside the construction of mixed-use real estate projects, underline the government's commitment to diversification and economic expansion. Ajman's economic vision is driven by policies aimed at regulatory efficiency, industrial growth, and the development of priority sectors such as health care and education. The emirate's long-term strategy aligns with Ajman Vision 2030, balancing economic progress with tradition to ensure sustainable growth. The streamlining of trade practices through digital solutions and regulatory enhancements is further strengthening its business environment, while increased integration of the industrial sector into global supply chains is positioning Ajman as a competitive player in international trade. Additionally, Ajman is leveraging its strategic location to expand its cultural and tourism offerings, reinforcing its appeal as a business and lifestyle destination. Jana Treeck, OBG's Managing Director for the Middle East, noted that Ajman's strategic approach to economic diversification is reinforcing its status as a key investment destination. 'Ajman's proactive economic policies, combined with regulatory reforms and infrastructure development, are enhancing the emirate's attractiveness to investors. Its efforts to modernise industries and integrate digital solutions reflect a broader commitment to fostering sustainable and inclusive economic growth,' Treeck said. Oliver Cornock, OBG's Editor-in-Chief, highlighted the broader implications of Ajman's evolving economic landscape. 'Ajman's ability to balance economic expansion with regulatory enhancements and industrial modernisation is shaping a business-friendly environment that is well positioned for long-term growth. As the emirate deepens its integration with global markets, its competitive advantages are expected to further strengthen investment prospects,' Cornock commented. The report features exclusive insights from key policymakers and business leaders, including Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Ajman Executive Council; Saif Al Suwaidi, Director-General, Ajman Department of Economic Development; Sheikh Sultan bin Mohammed Al Nuaimi, Director-General, Department of Ports and Customs Ajman; Ismail Al Naqi, Director-General, Free Zones Authority of Ajman; and Mahmood Khaleel Alhashmi, Director-General, Ajman Tourism Development Department. - TradeArabia News Service Copyright 2024 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (
Trade Arabia
05-05-2025
- Business
- Trade Arabia
Ajman an attractive base for SMEs, industries: report
The emirate of Ajman continues to establish itself as a competitive investment destination within the UAE's broader economy, says a new report. Its strategic proximity to Dubai enables seamless connectivity to global markets while maintaining lower operational costs, making it an attractive base for small and medium-sized enterprises (SMEs) and high-growth industries, says The Report: Ajman 2025 by Oxford Business Group (OBG). Developed in collaboration with the Ajman Executive Council, the report says Ajman's dynamic economic expansion is bolstered by a diversified industrial base and strategic location. The Report: Ajman 2025 offers a comprehensive analysis of the emirate's investment landscape and long-term growth strategies. The emirate has demonstrated resilience and growth across key sectors, particularly in manufacturing, real estate, and logistics, supported by initiatives such as the Ajman Free Zone and 100% foreign ownership laws. Infrastructure developments in transport and logistics, alongside the construction of mixed-use real estate projects, underline the government's commitment to diversification and economic expansion. Ajman's economic vision is driven by policies aimed at regulatory efficiency, industrial growth, and the development of priority sectors such as health care and education. The emirate's long-term strategy aligns with Ajman Vision 2030, balancing economic progress with tradition to ensure sustainable growth. The streamlining of trade practices through digital solutions and regulatory enhancements is further strengthening its business environment, while increased integration of the industrial sector into global supply chains is positioning Ajman as a competitive player in international trade. Additionally, Ajman is leveraging its strategic location to expand its cultural and tourism offerings, reinforcing its appeal as a business and lifestyle destination. Jana Treeck, OBG's Managing Director for the Middle East, noted that Ajman's strategic approach to economic diversification is reinforcing its status as a key investment destination. 'Ajman's proactive economic policies, combined with regulatory reforms and infrastructure development, are enhancing the emirate's attractiveness to investors. Its efforts to modernise industries and integrate digital solutions reflect a broader commitment to fostering sustainable and inclusive economic growth,' Treeck said. Oliver Cornock, OBG's Editor-in-Chief, highlighted the broader implications of Ajman's evolving economic landscape. 'Ajman's ability to balance economic expansion with regulatory enhancements and industrial modernisation is shaping a business-friendly environment that is well positioned for long-term growth. As the emirate deepens its integration with global markets, its competitive advantages are expected to further strengthen investment prospects,' Cornock commented.
Al Bawaba
04-05-2025
- Business
- Al Bawaba
Strategic investment insights to be explored in The Report: Kuwait 2025
Oxford Business Group (OBG) has signed a Memorandum of Understanding (MoU) with the Union of Investment Companies (UIC), marking the start of a strategic collaboration to support the development of The Report: Kuwait 2025. Under the terms of the agreement, UIC will serve as the publication's principal financial partner, contributing to the production of a comprehensive analysis of Kuwait's investment landscape. The partnership reflects Kuwait's broader efforts to increase international awareness of the country's evolving financial and investment ecosystem. Through this initiative, UIC will play an active role in providing analytical insights and facilitating access to key stakeholders, contributing to the report's in-depth research process. UIC's support will enable Oxford Business Group to conduct interviews and gather research across strategic sectors, while members of UIC will benefit from year-long access to OBG's global intelligence platform, which provides data and analysis on over 35 markets worldwide. Abdullah Hamad Al-Terkait, Chairman of UIC, said the collaboration aligns with their commitment to advancing Kuwait's role as a leading investment destination. 'Our partnership with Oxford Business Group underscores UIC's strategy to strengthen the local investment environment and increase Kuwait's visibility among global investors. By collaborating with an internationally recognised research platform, we aim to provide high-quality, transparent information that supports both domestic and international decision-makers,' he said. Cristina-Gabriela Mirica, OBG's Country Director for Kuwait, highlighted the importance of engaging with key financial institutions to ensure robust coverage of Kuwait's economic priorities. 'UIC brings deep insight into Kuwait's financial and investment sectors. Their participation will help shape a forward-looking analysis of market dynamics, regulatory changes and investment opportunities as the country advances its economic diversification goals,' she said. The Report: Kuwait 2025 will examine developments across sectors including financial services, real estate, energy, and technology. The publication comes at a time when Kuwait is intensifying efforts to support sustainable growth and private sector participation under the framework of New Kuwait Vision 2035. The report will feature interviews with high-profile public and private sector leaders and provide a data-driven overview of the investment climate and business outlook. This collaboration supports OBG's broader mission to deliver in-depth analysis across emerging markets and contributes to UIC's strategy to enhance transparency, support national development goals, and position Kuwait as a regional hub for business and investment. About Oxford Business Group Oxford Business Group (OBG) is a global research and advisory company with a presence in over 30 countries, spanning Africa, the Middle East, Asia, and the Americas. It is recognised internationally as a distinctive and respected provider of on-the-ground intelligence on world's fastest-growing markets, termed The Yellow Slice, in reference to OBG's corporate colour. Through its range of products – Economic News and Views; OBG CEO Surveys; OBG Events and Conferences; Global Platform, which hosts exclusive video interviews; and The Report publications – as well as its Advisory division, OBG offers comprehensive and accurate analysis of macroeconomic and sector-level developments for sound investment opportunities and business decisions. OBG provides business intelligence to its subscribers through multiple platforms, including its direct subscribers, Dow Jones Factiva subscribers, the Bloomberg Professional Services subscribers, Refinitiv's (previously Thomson Reuters) Eikon subscribers, and more.
